论文部分内容阅读
红细胞刺激药物(ESAs)的应用显著改善了终末期肾衰竭患者的贫血及预后。然而,血红蛋白水平并不是越高越好。迄今为止,贫血治疗的靶目标应多少才能使患者达到最佳预后并不明确。本文通过对不同血红蛋白与预后关系的相关研究,尤其是近期发表的在慢性肾脏疾病不同阶段患者中进行的大规模随机对照研究进行复习,从临床研究新结果认识纠正贫血目标值的变迁、红细胞刺激药物剂量和敏感性与预后的关系,并阐述目前对贫血纠正理念上的改变。
The use of erythrocyte stimulating drugs (ESAs) significantly ameliorates anemia and prognosis in patients with end-stage renal failure. However, hemoglobin levels are not as high as possible. So far, it has not been clear how much the target of anemia treatment should be to achieve the best prognosis for patients. This article reviewed the relationship between different hemoglobin and prognosis, especially in the recently published large-scale randomized controlled study in patients with different stages of chronic kidney disease review, from the new findings of clinical research to understand the changes in the target value of anemia, red blood cell stimulation Drug dose and sensitivity and prognosis, and explain the current concept of correction of anemia changes.